UNSPSC 51273913: Benzocaine/cetylpyridinium chloride

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class NT300. This VA Drug Class (NT300) classifies this compound as belonging to the group ANESTHETICS, MUCOSAL.

UNSPSC 51273913 Benzocaine/cetylpyridinium chloride is a Commodity code that in recent state and local procurement activity covers pharmaceutical and over-the-counter products distributed through competitive bidding and cooperative purchasing vehicles. State and local health agencies, county health departments, and multistate cooperative purchasing alliances solicit under this code to procure medications, naloxone kits, and OTC pharmaceutical products for community health initiatives and state health benefit programs. Vendors supplying under the code must maintain compliance with current Good Manufacturing Practices (cGMP), the Drug Supply Chain Security Act (DSCSA), FDA requirements, and state-specific procurement regulations including E-Verify employment verification and drug-free workplace certification. The code encompasses both direct pharmaceutical procurement from manufacturers and distribution through authorized wholesalers, with contracts typically structured on fixed-fee or net-price basis with administrative fees applied by cooperative purchasing entities.

Recent activity shows solicitations from Florida county health departments, Texas state health agencies, and multistate purchasing consortia. Seminole County, Florida issued IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with a response deadline of July 26, 2023, requiring quarterly deliveries to the Seminole County Community Health Building in Sanford with all shipping costs included in vendor bids. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026, to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program. Minnesota's Multistate Cooperative Purchasing Alliance (MMCAP) issued RFP S1070000015802 on January 20, 2026, for generic multi-source pharmaceuticals and OTC products, requiring proposals by March 26, 2026, with evaluation weighted 75 percent on price competitiveness and 25 percent across pricing format compliance, administrative fee structure, EDI capability, and fixed pricing terms.